scholarly journals mRNA Expression of the CUB and Sushi Multiple Domains 1 (CSMD1) and Its Serum Protein Level as Predictors for Psychosis in the Familial High-Risk Children and Young Adults

ACS Omega ◽  
2021 ◽  
Author(s):  
Eman Masoud Abd El Gayed ◽  
Mohamed Soliman Rizk ◽  
Ahmed Nabil Ramadan ◽  
Noha Rabie Bayomy
Keyword(s):  
Young Adults ◽  
High Risk ◽  
Mrna Expression ◽  
Serum Protein ◽  
Protein Level ◽  
Serum Protein Level ◽  
Children And Young Adults ◽  
Multiple Domains ◽  
Familial High Risk ◽  
High Risk Children

Serum Protein Concentrations in Normal Children

1971 ◽  
Vol 40 (1) ◽  
pp. 67-71 ◽  
Author(s):  
Berenice Abrams
Keyword(s):  
Young Adults ◽  
Serum Protein ◽  
Protein Level ◽  
Serum Proteins ◽  
Specific Component ◽  
Normal Children ◽  
Protein Levels ◽  
Group Specific Component ◽  
Α2 Macroglobulin ◽  
Age Range

1. Serum proteins were studied in 106 children ranging from 3 to 14 years using a modification of Laurell's method of quantitative immunoelectrophoresis. 2. Quantitative values are given for eleven proteins, viz.: α1 lipoprotein, α1 antitrypsin, α1 easily precipitable glycoprotein, α1 group specific component, α2 macroglobulin, caeruloplasmin, haptoglobin, transferrin, haemopexin, β lipoprotein, and β1AC(C3). 3. There were no significant differences in protein levels between the sexes, and no correlation between age and protein level within the age range studied. 4. The values were also compared with those of infants aged 6–12 months, young adults of 16–25 years, and adults of 16–65 years.

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 136-136 ◽  
Author(s):  
Ajay J Vora ◽  
Nicholas Goulden ◽  
Christopher D Mitchell ◽  
Rachael Hough ◽  
Clare Rowntree ◽  
...  
Keyword(s):  
Young Adults ◽  
High Risk ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Early Response ◽  
Treatment Intensification ◽  
Treatment Regimens ◽  
Poor Risk ◽  
Children And Young Adults ◽  
Minimal Residual

Abstract Abstract 136 Treatment modification according to Minimal Residual Disease (MRD) status at the end of induction and week 11 was investigated in a randomised control trial, UKALL 2003. Consecutively diagnosed children and young adults (up to age 25 years) with ALL were recruited from the UK and Republic of Ireland between October 2003 and June 2011. In the trial overall, we have observed a significant improvement in event-free survival (EFS) compared with its predecessor, ALL 97/99 (5-year EFS 87 vs 80%, log rank p<0.0005) most probably related to use of dexamethasone and pegylated asparaginase in all patients. Here we report the results of the MRD high risk randomisation which closed to recruitment on 30 June 2011. Patients in the trial were initially stratified by NCI risk, blast karyotype, and morphological marrow response at day 8/15 of induction for allocation to one of 3 treatment regimens, escalating in intensity (A, B, C). NCI standard risk (SR) patients received a 3 drug induction (Regimen A) whilst high risk (HR) patients received 4 drugs including daunorubicin (Regimen B). Patients with a slow early response at day 8 (NCI HR) or day 15 (NCI SR) of induction and patients with poor risk cytogenetics were transferred to Regimen C. Patients without poor risk cytogenetics and who had a rapid early response were eligible for the MRD randomisations. MRD was measured using Real Time Quantitative PCR with a sensitivity of 10−4. Five hundred and thirty three patients who had an MRD >/= 10−4at day 29 of induction were entered into a randomisation comparing standard treatment (Regimens A or B = standard arm, n = 266) with the more intensive Regimen C (intensification arm, n = 267). Of these, 332 (62%) were NCI SR and 201 (38%) NCI HR. With follow-up to October 2011 (median 3 years 11 months), the 5 year EFS is significantly better for patients in the intensification arm (91%) compared with the standard arms (82%) due to a halving of relapse risk (OR 0.57, 95% CI 0.34 – 0.95, 2p = 0.03). The improved EFS translates into a trend for better overall survival (OR 0.57, 95% CI 0.31 – 1.05, p= 0.07). There was no heterogeneity in benefit of Regimen C for sub-groups defined by NCI risk, immunophenotype or cytogenetics. The risk of death in remission was not significantly different in the two arms (Intensification = 7, Standard = 9, OR 0.76, 2p = 0.6) but there was an excess of SAEs and AEs related to asparaginase (hypersensitivity, p=0.0003 and pancreatitis, p = 0.01) and intravenous methotrexate (mucositis, p=0.03 and vomiting, p = 0.03) in the intensification arm. This randomised study provides evidence that treatment intensification is of benefit to patients defined as high risk by MRD measured at day 29 of induction. The excess toxicity related to asparaginase and intravenous methotrexate did not result in an increase in treatment related mortality. Taken together with the results of the low risk randomisation, reported at ASH in 2010, UKALL 2003 has demonstrated that within a NCI directed CCG backbone, MRD based stratification provides the optimal approach to risk directed therapy. Disclosures: No relevant conflicts of interest to declare.

University of Wisconsin experience treating adult ALL with the BFM regimen

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16501-16501
Author(s):  
S. C. Medlin ◽  
B. Kahl ◽  
W. Longo ◽  
E. Williams ◽  
J. Lionberger ◽  
...  
Keyword(s):  
Overall Survival ◽  
Young Adults ◽  
High Risk ◽  
Lymphoblastic Leukemia ◽  
Case Series ◽  
Adult Patients ◽  
Entire Group ◽  
Severe Toxicity ◽  
Risk Patients ◽  
Children And Young Adults

16501 Background: Berlin-Frankfurt-Munster therapy (BFM) is an effective regimen for acute lymphoblastic leukemia (ALL) in children and young adults (Lancet 2:921–924,1988). Treating children and young adults at higher risk for relapse with an augmented BFM was shown to increase both event free and overall survival (NEJM 338:23,1663–1671,1998). Outcomes using standard BFM or augmented BFM in adults are unknown. Methods: This is a case-series of 29 adult patients treated with the BFM regimen. Patients were stratified into low, intermediate and high-risk groups based upon the following characteristics: age, white blood cell count, adverse cytogenetics and absence of CD 10. Low risk patients received the standard BFM regimen. Intermediate risk patients were given augmented BFM if less than 50 years old, standard BFM if older than age 50. High-risk patients received augmented BFM. Cranial irradiation was omitted in most patients (25/29). Events were defined as relapse, death from any cause, and stopping treatment for any reason. Results: Fifteen patients (median age 38, range 19–70) were treated with standard BFM and 14 patients (median age 37, range 21–72) with augmented BFM. Complete remission at day 28 was 93% (27/29). For the entire group, the 3-year overall survival was 60% with a 3-year event free survival of 45%. Patients treated with augmented BFM experienced a 3-year EFS, PFS, OS of 26%, 43%, and 48% respectively. Patients treated with standard BFM had a 3-year EFS, PFS, OS of 60%, 78%, and 78% respectively. Toxicity was common with significant neuropathy and neutropenic fever occurring in 83% and 48% respectively. Septic shock occurred in 17% of patients. Severe toxicity resulted in 1 death and discontinuation of BFM in 3 patients. The entire regimen was completed in 33 % of those treated with augmented BFM and 71% of those treated with standard BFM. Conclusion: Standard BFM is an effective and tolerable regimen for treatment of adult ALL. Augmented BFM is a difficult regimen for adult patients to complete. For both regimens, the 3-year PFS and OS compare favorably to other published regimens. No significant financial relationships to disclose.

scholarly journals ELEKTROFORESIS PROTEIN SERUM PASIEN DENGAN KADAR PROTEIN NORMAL

2018 ◽  
Vol 15 (3) ◽  
pp. 87
Author(s):  
Tiene Rostini ◽  
Coriejati Rita
Keyword(s):  
Serum Protein ◽  
Total Protein ◽  
Protein Level ◽  
Protein Electrophoresis ◽  
Serum Protein Electrophoresis ◽  
Total Protein Level ◽  
Normal Limits ◽  
Nephritic Syndrome ◽  
Serum Protein Level ◽  
Electrophoresis Pattern

Serum protein electrophoresis pattern can assist in diagnosis of liver disease, hematological disorders, renal disorders andgastrointestinal disease. Measurement of total protein level in the serum cannot detect any disorders in patient with normal limit ofserum total protein level. The aim of this study; was to evaluate the serum protein electrophoresis pattern in patient with normal limitsof serum protein level. This research was carried out by descriptive retrospective study using the electrophoresis data from patients’medical record at the Clinical Pathology Department, Dr. Hasan Sadikin General Hospital Bandung. The data of serum electrophoresis (bySebia gel electrophoresis) were grouped based on disease or disorders, and confirmed with the diagnosis derived from patient’s medicalrecord. Inclusion criteria of samples if ; the electrophoresis data were available, serum total protein level within normal limits (6.4–8.3mg/dL), and the data of electrophoresis taken from medical record were taken from August 2006 until August 2008. The result foundso far was, there were 240 data of electrophoresis from patients with serum protein level within normal limits (6.4–8.3 mg/dL). theinterpretation of electrophoresis consist of: 1) inflammation (149 patients; 62.2% ; sensitivity 83.7%, specificity 86,5%) 2) Cirrhosis(46 patients ; 19.2% ; sensitivity 87.5% ; specificity 88.4%) 3) Nephritic syndrome (15 patients ; 6.2%; sensitivity 53%; specificity96.9% 4) Monoclonal gammophaty (15 patients(6.2% ; sensitivity 80% ; specificity 98.7%) 5) Normal pattern in 15 patient (6.2%).This study found abnormal serum protein electrophoresis pattern in the condition of inflammation, Cirrhosis, Nephritic Syndrome, andMonoclonal gammophaty. It can be concluded that many disorders could be detected in patient with serum protein level within normallimits such as: inflammation, cirrhosis, nephritis syndrome and monoclonal gammophaty by abnormal electrophoresis pattern

LEVELS AND PARTITION OF THE FOWL'S SERUM PROTEINS IN RELATION TO AGE AND EGG PRODUCTION

1955 ◽  
Vol 33 (1) ◽  
pp. 891-903 ◽  
Author(s):  
W. E. Vanstone ◽  
W. A. Maw ◽  
R. H. Common
Keyword(s):  
Serum Protein ◽  
Protein Level ◽  
Egg Production ◽  
Serum Proteins ◽  
Electrophoretic Pattern ◽  
Total Serum Protein ◽  
Total Serum ◽  
Zone Electrophoresis ◽  
Serum Protein Level ◽  
New Protein

The level of total serum protein in the fowl has been followed from the 14th day of incubation to the 13th week of egg production. Serum proteins have been fractionated concurrently by zone electrophoresis in filter paper. Serum protein level in the 14-day embryo was 0.9 gm./100 ml. and the protein comprised a prealbumin fraction, albumin, α2- and β-globnlins. Sera from chicks aged seven days no longer contained a prealbumin fraction but α1-,α3- and γ-globulin fractions had appeared by this stage and the protein level had reached 2.3 gm./100 ml. Total serum protein in females increased to a maximum of about 5.4 gm./100 ml. in the week before laying of the first egg. By that time two new protein fractions had appeared. These new fractions accounted for the greater part of the increase over the levels (4.0 gm./100 ml.) prevailing in the prepuberal stage. Serum protein level declined during the first three weeks of laying to average levels below 4.0 gm./100 ml.; and this decline appeared to affect albumin and α1-globulin as well as the new fractions. As laying progressed, the total serum protein tended to regain a level around 4.0 gm./100 ml. The electrophoretic pattern also tended to return towards that prevailing in the week before laying. Some tentative correlations of the results of zone electrophoresis with published results for free electrophoresis of fowl serum proteins are presented.

Blood Serum Protein Level as a Function of Age

1959 ◽  
Vol 18 (3) ◽  
pp. 983-990 ◽  
Author(s):  
B. L. Larson ◽  
R. W. Touchberry
Keyword(s):  
Blood Serum ◽  
Serum Protein ◽  
Protein Level ◽  
Serum Protein Level ◽  
Blood Serum Protein
Sign in / Sign up

Export Citation Format

Share Document